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Metabolic Syndrome: Gender Differences
Introduction
Metabolic syndrome is commonly defined as the association 
of multiple risk factors for the development of atherosclerotic 
disease. Despite the different definitions of diagnostic criteria, 
the presence of at least three of the following conditions defines 
the clinical presentation of the metabolic syndrome: atherogenic 
dyslipidemia (low levels of HDL cholesterol, high levels of 
triglycerides, apolipoprotein B and small and dense LDL), basically 
high levels of systolic and diastolic blood pressure, impaired 
fasting glycemia and abdominal obesity [1]. Primary pathogenic 
mechanisms underlying metabolic syndrome are mainly due to 
insulin resistance (or poor insulin sensitivity) and visceral obesity. 
Insulin resistance, a condition where insulin determines a lower 
biological effect than expected, is largely represented in patients 
with metabolic syndrome and it is associated with a high risk of 
developing type 2 diabetes in the short term. Obesity and physical 
inactivity represent predisposing conditions for the development 
of metabolic syndrome and perhaps represent the main mechanism 
underlying the epidemic of metabolic syndrome, as observed in recent years.
Other precipitating factors of the development of the syndrome 
are represented by advanced age, hormonal imbalances, such 
as those observed during menopause. Patients diagnosed with 
metabolic syndrome have a doubled risk of atherosclerotic disease. 
Some authors questioned the utility of the diagnosis of metabolic 
syndrome in the management of prevention and definition of 
individual cardiovascular risk, focusing the attention on the 
individual assessment of cardiovascular risk factors. Actually, the 
coexistence of risk factors in the metabolic syndrome confers a much 
higher risk than the value simply obtained summing the individual 
factors. A further advantage deriving from the identification of a 
cluster of risk factors is observed in the syndrome, is represented 
by the greater attention paid to an early correction of lifestyle. Thus, 
the diagnosis of metabolic syndrome allows to the identification of subjects at risk of developing cardiovascular disease at an 
early stage. Furthermore, when adopting diagnostic criteria, it 
is necessary to take into account their simple applicability which 
involves the execution of few and targeted routine laboratory tests 
and simple anthropometric measurements. The prevalence of 
 
metabolic syndrome is exponentially increasing across the planet, 
as reflecting the parallel increase in obesity, expected to continue 
increasing in the next decade.
It is incredible to see that, while a part of the population 
suffers consequences of hunger, an increasingly part suffers 
consequences of obesity. One of the most discussed aspects in the 
various diagnostic classifications is the adjustment of the waist 
circumference based on the demographic characteristics of the 
examined population. In our country, data from population studies 
show a prevalence of the syndrome, defined by the ATP III criteria [1], ranging from 2 to 31% in adult men and from 1 to 35% for adult 
women.
Numerous observational and prospective studies have shown a 
different impact and distribution of cardiovascular disease in both 
sexes; in fact, women seem to develop cardiovascular events 10 
years later than men with a marked increase of incidence in the age 
range mostly corresponding to the beginning of the menopausal 
period. But this gap is restricting, and it precisely may be due also 
to the metabolic syndrome. Among the cardiovascular risk factors 
to which women are exposed during their lifetime, age, sex and 
possible genetic substrate are not modifiable, while most of the risk 
factors such as arterial hypertension, dyslipidemia, obesity, glucose intolerance, cigarette smoking, diabetes mellitus and sedentariness 
are broadly reversible conditions. Importantly, among these, 
the first 4 represent components of the metabolic syndrome, a 
condition associated with a risk 5 times greater than developing 
diabetes and 3 times greater than developing cardiovascular death secondary to infarction or stroke [2]. In particular, abdominal 
obesity and the associated insulin resistance can contribute to the 
progression of dyslipidemia, to an increase in oxidative stress and 
therefore to endothelial dysfunction and vascular inflammation, 
leading to a prothrombotic state and accelerated atherosclerosis, in 
association with a large series of metabolic alterations.
We have at this point to clarify the difference between sex 
and gender: sex includes everything related to biology (genes, 
hormones, etc.), while the concept of gender, brought to the 
biomedical and human sciences, includes cultural, environmental 
and social influence [3]. Post-menopausal women very often 
Mini Review
Open Access 
Research in Anatomy C CRIMSON PUBLISHERSWings to the Research
1/3Copyright © All rights are reserved by Maria Grazia Modena.
Volume 1 - Issue - 5
ISSN: 2577-1922
Open Acc Res Anatomy Copyright © Maria Grazia Modena
2/3How to cite this article: Elisa L, Alberto C, Valentina M, Maria G M. Metabolic Syndrome: Gender Differences.Open Acc Res Anatomy. 1(5). OARA.000524.2018.
Volume 1 - Issue - 5
develop metabolic syndrome, much more then men of same age: 
this is an example of gender difference mainly due to environment 
and life- style. According to the definitions of metabolic syndrome 
reported by ATP III and IDF respectively, the prevalence of metabolic 
syndrome in postmenopausal women in the EUROASPIRE study 
was 56% and 72% respectively, compared to 40% and 59% of 
men [4]. Such a high prevalence is supported by the fact that 
menopause is associated with an increase in sedentariness as well 
as a significant increase in the visceral obesity rate facilitated by 
estrogen deficiency, which contributes to the development of 
dyslipidemia, insulin resistance with reduced glucose tolerance, 
increased of pressure levels, sympathetic hyperactivity and pro-
inflammatory and prothrombotic state [5]. 
It has been observed in parallel, how these metabolic alterations 
are more prevalent in post- menopause and in men over 50 years 
of age, and that the prevalence of the already elevated metabolic 
syndrome during the menopausal transition, undergoes a further 
increase in the postmenopausal period (SWAN study) [5]. Insulin 
resistance and visceral obesity seem to play a primary role in the 
pathogenesis of the metabolic syndrome in the post-menopausal 
phase, which, after a progressive reduction during the transition 
phase, is separate from an insulin sensitivity index markedly 
lower than that of the premenopausal period, regardless of the presence of obesity and plasma levels of blood sugar and fasting 
insulin (Figure 1). In confirmation of the central role of estrogenic 
deficiency in the genesis of this phenomenon, in humans no similar 
changes in insulin sensitivity have been observed in the same age 
group. A longitudinal study on 543 women in the perimenopausal 
period followed for 6 years, showed an absolute increase in fat 
mass of 3.4kg and an increase in the waist circumference equal to 
5.7cm [6]. In confirmation of the relationship between menopause 
and metabolic alterations, these parameters are proportionally 
correlated with the FSH plasma levels. Furthermore, the increase in visceral fat is inversely related to insulin sensitivity and associated 
with an increase in triglycerides, free fatty acids and small and 
dense LDL. Visceral obesity is the condition responsible for the 
pathophysiological relationship between insulin resistance and 
metabolic syndrome in females and is associated with an increased 
production of adipokines such as leptin, adiponectin and resist in.
Figure 1:
These proteins, synthesized by adipocytes, bind to receptors 
mainly present in brain, endothelial and vascular walls. In the transition from premenopausal to postmenopausal period, leptin 
levels progressively increased, indicating that visceral fat can 
determine a pro- inflammatory and pro-coagulation state such 
as observed in patients with metabolic syndrome, through the 
secretion of this peptide. In contrast, plasma adiponectin levels 
were lower in the postmenopausal period and inversely correlated 
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with insulin sensitivity [7]. The systemic inflammatory status 
observed in postmenopause is associated with a worsening of 
endothelial function assessed as flow-mediated dilation of the 
brachial artery. Endothelial dysfunction, present since the early 
stages of the menopausal period, is associated with a greater 
development of arterial hypertension after a follow-up of 3.6 years 
[8]. Furthermore, our study has shown that post-menopausal 
hypertension associated with metabolic syndrome, compared to a 
similar condition without metabolic syndrome, is associated with 
greater organ damage, worse endothelial function and is more 
resistant to therapy [9].
Given the central role of estrogenic deficiency in determining 
the metabolic changes observed in menopause, several studies have 
evaluated the impact of hormone replacement therapy on various 
components of the metabolic syndrome. However, while reducing 
estrogen, abdominal obesity, insulin resistance, the development 
of new cases of diabetes, the LDL/HDL cholesterol ratio, blood 
pressure values and inflammatory indices, they increased protein 
C and reduced protein S, showing a potential prothrombotic 
effect [10]. Therefore, the total overall effect of postmenopausal 
hormone therapy seems to be an increase in arterial and venous 
thrombotic events (data from the WHI and HERS studies), so it is 
no longer recommended, and the suspension is rather preferable 
for some categories at risk. More than 50% of women over the age 
of 60 years present current diagnostic criteria of the metabolic 
syndrome with an increased cardiovascular risk that arouses strong social and economic concerns. A programmatic effort must 
focus on nutrition education, physical activity and implementation 
of the therapeutic strategies recommended by the guidelines to 
substain healthcare and social costs. The drugs should be able to 
control the risk factors, to improve and not to worsen the insulin 
resistance and, possibly, to act also on other conditions associated 
with the metabolic syndrome, such as small and dense LDL, 
microalbuminuria, oxidative stress, endothelial dysfunction and 
pro-coagulation status.
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